Blood Platelets and Chloroquine

References

• Stillman J S. Antimalarials. Textbook of Rheumatology, W. N. Kelley, E. D. Harris, S Ruddy, C. B. Sledge. WB Sanders Co, Philadelphia 1981; 785–795
   Google Scholar
• Verdier F, Le Bras J, Clavier F, Hatin I, Blayo M C. Chloroquine uptake by Plasmodium falciparum-infected human erythrocytes during in vitro culture and its relationship to chloroquine resistance. Antimicrob Agents Chemother 1985; 27: 561–567
   PubMed Web of Science ®Google Scholar
• Webster W L. Drugs used in the chemotherapy of protozoal infections. The Pharmacological Basis of Therapeutics8th edition, L. S. Goodman, A Gilman's. Pergamon Press. 1990; 978–998
   Google Scholar
• McChesney E W., Fitch C D. 4-aminoquinolines. Antimalarial drugs II. Current antimalarials and new drug developments. Handbook of experimental pharmacology, W Peters, WMG Richards. Springer Verlag. 1984; vol 68: 3–60, II
   Google Scholar
• Prasad R N., Ganguly N K., Mahajan R C. Immunopharmacology of chloroquine. Trans Roy Soc Trop Med Hyg 1987; 81: 168–169
   PubMed Web of Science ®Google Scholar
• Bridges J M., Baldini M. Effect of quinidine and related compounds on uptake and release of serotonin by blood platelets. Nature 1966; 210: 1364–1365
   PubMed Web of Science ®Google Scholar
• Prada M, Pletscher A. Accumulation of basic drugs in 5–hydroxytryptamine storage organelles of rabbit platelets. Eur J Pharmacol 1975; 31: 179–185, Da
   Google Scholar
• Lagarde M, Dechavane M, Bryon P A. Chloroquine et sérotonine plaquetaire. Experientia 1975; 31: 233–234, Mise en évidence d'une inhibition compétitive de la captation de sérotonine
   PubMedGoogle Scholar
• Bergquist Y, Domeij-Nyberg B. Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma. J Chromatogr 1983; 272: 137–148
   PubMed Web of Science ®Google Scholar
• Costa J L., Fay D D., Kirk K L. Quinacrine and other basic amines in human platelets. Res Commun Chem Pathol Pharmacol 1984; 43: 24–42, Subcellular compartmentation and effect on serotonin
   Google Scholar
• Nosál R., Ericsson Ö, Sjöqvist F. Distribution of chloroquine in human blood fractions. Meth Find Exptl Clin Pharmacol 1988; 10: 581–587
   PubMed Web of Science ®Google Scholar
• Bertrand E, Cloitre B, Ticolat R, et al. Antiaggregation action of chloroquine. Med Trop Mars 1990; 50: 143–146
   PubMedGoogle Scholar
• Cummins D, Faint R., Yardumian D A., Dawling S, Mackie I, Macchin S J. The in vitro and ex vivo effect of chloroquine sulfate on platelet function: implications for malaria prophylaxis in patients with impaired haemostasis. J Trop Med Hyg 1990; 93: 112–115
   PubMed Web of Science ®Google Scholar
• Jančinová V, Nosal R., Petrikova A M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res 1994; 74: 495–504
   PubMed Web of Science ®Google Scholar
• Nosál R., Petriková M. Chloroquine inhibits stimulated platelets at the arachidonic acid pathway. Thromb Res 1995; 77: 531–542
   PubMed Web of Science ®Google Scholar
• Nilsson J, Thyberg J, Heldin C H., Westermark B, Wasteson A. Surface binding and internalization of platelet-derived growth factor in human fibroblasts. Proc Natl Acad Aci (USA) 1983; 80: 5592–5596
   PubMed Web of Science ®Google Scholar
• Blumberg N, Masel D, Mayer T, Horan P, Heal J. Removal of HLA-A, B antigens from platelets. Blood 1984; 63: 448–450
   PubMed Web of Science ®Google Scholar
• Andersag H. Antimalariamittel aus der Gruppe halogen-substituirter Chinolinverbindungen. Chem Ber 1948; 81: 499–507
   Google Scholar
• Wiseloge F Y. A survey of antimalarial drugs, J. W. Edwards. Ann Arbor, Michigan 1941-1945; I: 2–46, 1946
   Google Scholar
• Aikawa M. High-resolution autoradiography of malarial parasites treated with [3H]chloroquine. Am J Pathol 1972; 67: 277–284
   PubMed Web of Science ®Google Scholar
• Yayon A, Ginsburg H. Chloroquine inhibits the degradation of endocytic vesicles in human malaria parasites. Cell Biol Int Rep 1983; 7: 895
   PubMedGoogle Scholar
• Kogstad D J., Schlezinger P H. The basis of antimalarial action. J Trop Med Hyg 1987; 36: 213–220, Non-weak base effects of chloroquine on acid vesicle pH
   Google Scholar
• Fitch C D., Butha P, Kajananggulpan P, Chevli P. Ferriprotoporphyrin IX: a mediator of the antimalarial action of oxidants and 4-aminoquinoline drugs. Prog Clin Biol Res 1984; 155: 119–130
   PubMedGoogle Scholar
• Kwakye-Berko F, Meshnick S R. Binding of chloroquine to DNA. Molec Biochem Parasitol 1989; 35: 51–56
   PubMed Web of Science ®Google Scholar
• Yayon A, Cabantchik Z I., Ginsburg H. Susceptibility of human malaria parasites to chloroquine is pH dependent. Proc Natl Acad Sci (USA) 1985; 82: 2784–2788
   PubMed Web of Science ®Google Scholar
• Ferrari V, Cutler D J. Temperature dependence of the acid dissociation constants of chloroquine. J Pharm Sci 1987; 76: 554–556
   PubMed Web of Science ®Google Scholar
• Ferrari V, Cutler D J. Uptake of chloroquine by human erythrocytes. Biochem Pharmacol 1990; 39: 753–762
   PubMed Web of Science ®Google Scholar
• McChesney E W., Banks W F., McAuliff I P. Laboratory studies of the 4-aminoquinoline antimalarials II. Antibiot Chemother 1962; 12: 583–594, Plasma levels of chloroquine and hydroxychloroquine in man after various oral dosage regimens
   Google Scholar
• Gustavson L L., Walker O, Alvan G, et al. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol 1983; 15: 471–479
   PubMed Web of Science ®Google Scholar
• McChesney E W., Banks W F. Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats. Toxicol Appl Pharmacol 1965; 7: 627–636
   PubMed Web of Science ®Google Scholar
• Warhurst D C. Mechanism of chloroquine resistance in malaria. Parasitol Today 1988; 4: 211–213
   PubMedGoogle Scholar
• Yi-Fan L, Peterson J W., Jackson C H., Reitmayer J C. Chloroquine inhibition of cholera toxin. FEBS Lett 1990; 275: 143–145
   PubMed Web of Science ®Google Scholar
• De Duve C., De Barsy T, Poole B, Trouet A, Tulkens P. Van Hoof. Lysosomotropic agents. Biochem Pharmacol 1974; 23: 2495–2531
   PubMed Web of Science ®Google Scholar
• Hollemans M, Elferink K O., DeGroot P G., Strijland A, Tager J M. Accumulation of weak bases in relation to intralysosomal pH in cultured human skin fibroblasts. Biochim Biophys Acta 1981; 643: 140–151, 35
   PubMedGoogle Scholar
• Hostetler K Y. The role of phospholipases in human diseases. Phospholipids and cellular regulation, J. F. Kuo. CRC Press, Boca Raton 1985; vol I: 181–206, (ed). Fl
   Google Scholar
• Dingle J T., Barret A J. Uptake of biologically active substances by lysosomes. Proc R SOC Lond 1969; 173: 85–93
   PubMed Web of Science ®Google Scholar
• Ohkuma O, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci (USA) 1978; 75: 3327–3331
   PubMed Web of Science ®Google Scholar
• Poole B, Ohkuma S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol 1981; 90: 665–669
   PubMed Web of Science ®Google Scholar
• Kubo M, Hostetler K Y. Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase. A., Biochemistry 1985; 24: 6515–6520
   Google Scholar
• Grabner R. Influence of cationic amphiphilic drugs on the phosphatidylcholine hydrolysis by phospholipase. A., Biochem Pharmacol 1987; 36: 1063–1067
   PubMed Web of Science ®Google Scholar
• Lüllman H, Lüllman-Rauch R. Wassermann O. Biochem Pharmacol 1978; 27: 1103–1108, Lipidosis induced by amphiphilic cationic drugs
   PubMed Web of Science ®Google Scholar
• Hostetler K Y., Matsuzawa Y. Studies on the mechanism of drug-induced lipidosis. Biochem Pharmacol 1981; 30: 1121–1126, Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C
   PubMed Web of Science ®Google Scholar
• Kodavanti U P., Mehendale H M. Cationic amphiphilic drugs and phospholipid storage disorders. Pharmacol Rev 1990; 42: 327–354
   PubMed Web of Science ®Google Scholar
• Lüllman H, Wehling M. The binding of drugs to different polar lipids in vitro. Biochem Pharmacol 1978; 28: 3409–3415
   Web of Science ®Google Scholar
• Joshi U M., Mehendale H M. Drug-induced pulmonary phospholipidosis. Comm Toxicol 1989; 3: 91–115
   Google Scholar
• Pečivová J, Drábiková K, Nosal R. The effect of chloroquine on mast cell membranes. Agents Actions 1994; 41: C43–C44
   Google Scholar
• Lorenz H P., Pletscher A. Flashing phenomenon in blood platelets stained with fluorescent basic drugs. Experientia 1975; 31: 593–594
   PubMedGoogle Scholar
• Lorenz H P., Da Prada M, Rendu F, Pletscher A. Mepacrine, a tool for investigating the 5-hydroxytryptamine organelles of blood platelets by fluorescent microscopy. J Clin Lab Med 1977; 89: 200–206
   Web of Science ®Google Scholar
• Picotti G B., Pletscher A. Uptake and liberation of mepacrine in blood platelets. Naun Schmied Arch Pharmacol 1976; 292: 127–131
   Google Scholar
• Costa J L., Murphy D L. Unique specializations for the subcellular compartmentation of amines in pig and human platelets. Platelets: Cellular response mechanisms and their biological significance, A Rotman, F. A. Meyer, C. Gitter, A Silberberg. John Willey & Sons Ltd. 1980; 233–247
   Google Scholar
• Nosál R., Drábiková K, Pečivová J. Effect of chloroquine on isolated mast cells. Agents Actions 1991; 33: 37–40
   PubMedGoogle Scholar
• Matsuzawa Y, Hostetler K Y. Inhibition of lyzozomal phospholipase A and phospholipase C by chloroquine and 4,4′-bis(diethylamino-ethoxy)α, β-diethyldiphenylethane. J Biol Chem 1980; 255: 5190–5194
   PubMed Web of Science ®Google Scholar
• Hostetler K Y., Reasor M, Yazaki P J. Chloroquine-induced phospholipid fatty liver. J Biol Chem 1985; 260: 215–219, Measurement of drug and lipid concentration in rat liver lysosomes
   PubMed Web of Science ®Google Scholar
• Winocour P D., Kinlough-Rathbone R L., Mustard I. The effect of the phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface. Thromb Haemostas 1981; 45: 257–262
   PubMed Web of Science ®Google Scholar
• Billah M M., Lapetina E G., Cautrecasas P. Phospholipase A, activity specific for phosphatidic acid: a possible mechanisms for the production of arachidonic acid in platelets. J Biol Chem 1981; 256: 5399–5403
   PubMed Web of Science ®Google Scholar
• McCrea J M., Robinson P, Gerrard J M. Mepacrine(quinacrine) inhibition of thrombin-induced platelet responses can be overcome by lysophosphatidic acid. Biochim Biophys Acta 1985; 842: 189–194
   PubMedGoogle Scholar
• Brindley D N., Bowley M. Drugs affecting the synthesis of glycerides and phospholipids in rat liver. Biochem J 1975; 148: 461–469
   PubMed Web of Science ®Google Scholar
• Lapetina E G., Billah M M., Cautrecasas P. The initial action of thrombin on platelets. J Biol Chem 1981; 256: 5037–5040, Conversion of phosphatidylinositol to phosphatidic acid preceding the production of arachidonic acid
   PubMed Web of Science ®Google Scholar
• Blackwell G J., Duncombe W G., Flower R J., Parsons M F., Vane J R. The distribution and metabolism of arachidonic acid in rabbit platelets during aggregation and its modification by drugs. Br J Pharmac 1977; 59: 353–366
   PubMed Web of Science ®Google Scholar
• Dise C A., Burch J W., Goodman D. B.P. Direct interaction of mepacrine with erythrocytes and platelet membrane phospholipid. J Biol Chem 1982; 257: 4701–4704
   PubMed Web of Science ®Google Scholar
• Hurst N P., French J K., Bell A L., et al. Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid release by human blood monocytes. Biochem Pharmacol 1986; 35: 3083–3089
   PubMed Web of Science ®Google Scholar
• Chan A C., Pritchard E T., Gerrard J M., Man RYK, Choy P C. Biphasic modulation of platelet phospholipase A, activity and platelet aggregation by mepacrine(quinacrine). Biochim Biophys Acta 1982; 713: 170–172
   PubMed Web of Science ®Google Scholar
• Mahadevapa V G., Sicilia F. Mobilization of arachidonic acid in thrombin-stimulated human platelets. Biochem Cell Biol 1990; 68: 520–527
   PubMed Web of Science ®Google Scholar
• Nordhagen R., Flaathen S T. Chloroquine removal of HLA antigens for the platelet immunofluorescence test. Vox Sang 1985; 48: 156–159
   PubMed Web of Science ®Google Scholar
• Metcalfe P, Minchinton R M., Murphy M F., Waters A H. Use of chloroquine-treated granulocytes and platelets in the diagnosis of immune cytopenias. Vox Sang 1985; 49: 340–345
   PubMed Web of Science ®Google Scholar
• Kao K J., Cook D J., Scornik J C. Quantitative analysis of platelet surface HLA by W6/32 anti-HLA monoclonal antibody. Blood 1986; 68: 627–632
   PubMed Web of Science ®Google Scholar
• Collins J, Aster R M. Use of immobilized platelet membrane glycoproteins for the detection of platelet-specific alloantigens in solid-phase ELISA. Vox Sang 1987; 53: 157–161
   PubMed Web of Science ®Google Scholar
• Kao K J. Selective elution of HLA antigens and beta 2-microglobulin from human platelets by chloroquine diphosphate. Transfusion 1988; 28: 14–17
   PubMed Web of Science ®Google Scholar
• Langscheidt F, Kiefel V, Santoso S, Nau A, Mueller-Eckhard C. Quantitation of platelet antigens after chloroquine treatment. Eur J Haematol 1989; 42: 186–192
   PubMed Web of Science ®Google Scholar
• Kuijpers R W., Ouwehand W H., Bleeker P M., Christie D, vom dem Borne A E. Localization of the platelet-specific HLA-2 alloantigens on the N-terminal globular fragment of platelet glycoprotein Ib alpha. Blood 1992; 79: 283–288
   PubMed Web of Science ®Google Scholar
• Neumüller J, Tohidast-Akrad M, Fischer M, Mayr W R. Influence of chloroquine or acid treatment of human platelets on the antigenicity of HLA and the thrombocyte-specific glycoproteins Ia/IIa, IIb and IIb/IIIa. Vox Sang 1993; 65: 223–231
   PubMed Web of Science ®Google Scholar
• Ross R., Glomsted J A., Karyia B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci (USA) 1974; 71: 1207–1210
   PubMed Web of Science ®Google Scholar
• Ross R. Platelet derived growth factor. Ann Rev Med 1987; 38: 71–79
   PubMed Web of Science ®Google Scholar
• Bottger B A., Sjolund M, Thyberg I. Chloroquine and monensin inhibit induction of DNA synthesis in rat arterial smooth muscle cells stimulated with platelet-derived growth factor. Cell Tissue Res 1988; 252: 275–285
   PubMed Web of Science ®Google Scholar
• Polet H. Effects of platelet-derived growth factor on degradation, nuclear translocation of non-histone proteins and DNA synthesis. Proc SOC Exp Biol Med 1992; 199: 417–423
   PubMed Web of Science ®Google Scholar
• Ostman A, Thyberg J, Westermark B, Heldin C H. PDGF-AA and PDGF-BB biosynthesis: proprotein processing in the Golgi complex and lysosomal degradation of PDGF-BB retained intracellularly. J Cell Biol 1992; 118: 509–519
   PubMed Web of Science ®Google Scholar
• Fuhrman B, Maor I, Rosenblat M, Dankner G, Aviram M, Brook J G. Modification of LDL by platelet secretory products induced enhanced uptake and cholesterol accumulation in macrophages. Biochim Med Metab Biol 1989; 42: 9–20
   PubMedGoogle Scholar
• Maor I, Brook G J., Aviram M. Platelet secreted lipoprotein-like particle is taken up by the macrophage scavenger receptor and enhances cellular cholesterol accumulation. Atheroscler 1991; 88: 163–174
   PubMed Web of Science ®Google Scholar
• Bell W R. Complications of thrombolytic therapy-bleeding and rethrombosis. Controversies in Coronary Thrombolysis, S Sherry, R Schrdher, C Kluft, A. J. Six, K. L. Mettinger. Current Medical Literature Ltd, London 1989; 59–69
   Google Scholar